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The extension site is shown (red arrow). An asterisk marks the chiral carbon which is inverted in the negative control (-)JQ1.
Supplementary Figure 3. Distances between the two recruiters within a PROTAC or CLIPTAC.
Maximum and minimum achievable distances between the linkage atoms in JQ-1 based PROTACs dBET1 and ARV-825 compared with JQ1-CLIPTAC. Calculations were performed using MOE 2015 in the absence of proteins. The results indicate that JQ1-CLIPTAC is able to elicit a similar range of proximities between the protein of interest (BRD4) and the E3 ligase (CRBN) as ARV-825.
Supplementary Figure 4. LC-MS profile of the click reaction between JQ1-TCO and Tz-thalidomide.
LC-MS analysis of Tz-thalidomide (1, black), JQ1-TCO (2, pink) and the reaction mixture after 15 min (blue). Minor peaks are presumed to arise from diastereoisomers formed in the click reaction and which are not expected to show differences in biological activity.
Supplementary Figure 5. Bioassay evaluation of JQ1 derivatives vs the BRD4 bromodomain BRD4-2.
Affinity of JQ1 (n=1), JQ1-TCO (2, n=2), JQ1-CLIPTAC (3, n=2) and (-)JQ1-TCO ((-)2, n=2) for BRD4-2 bromdomain as determined by AlphaScreen histone peptide displacement assays.
Supplementary Figure 7. Selectivity profile of JQ1-TCO against the BET family.
The selectivity profile of JQ1-TCO 2 (10 µM, duplicate) was assessed using thermal shift assays (Reaction Biology) against the BET family. Red spots are representative of the ΔTm shifts in degrees Celsius obtained from the thermal shift assay.
Supplementary Figure 8. LC-MS profile of the click reaction between Probe 1-TCO and Tz-thalidomide.
LC-MS analysis of Probe 1 (pink), Tz-thalidomide (black) and the reaction mixture after 15 min (blue). The double peaks are ascribed to diastereoisomers of ERK-CLIPTAC formed in the click reaction which are not expected to show differences in biological activity.
Supplementary Figure 9. Bioassay evaluation of Tz-thalidomide 1 against ERK2.
Table summarising the concentration-dependent inhibition of recombinant ERK2 by Tzthalidomide 1 as determined by time-resolved fluorescence assay (n = 2, 46 ± 4% inhibition @ 30 µM). Full assay conditions are given in the Experimental section. A375 cells were treated with Probe 1 for 4 h followed by thalidomide (10 µM) and Tz-thalidomide (1 µM) for 18 h. Following cell lysis, the levels of ERK1/2 were studied by Western Blots.
Synthesis of CLIPTAC Precursor Components
Tz-thalidomide 1 was synthesised in 7 steps as illustrated in Supplementary Scheme S1a, starting with the opening of the anhydride moiety of compound 11 with methanol and methylation of the carboxylic acid generated to give the dimethyl ester 12. Alkylation of the phenol group was performed under Mitsunobu conditions to afford compound 13 which underwent a selective hydrolysis under basic conditions followed by amination with the hydrochloride salt of 3-amino piperidine-2,6-dione, and hydrolysis of the tert-butyl ester under acidic conditions to form the diacid 14. The tetrazine moiety was inserted by amide coupling to give Tz-thalidomide 1. Finally, the imide group was methylated to form Tzthalidomide-Me 4, an inactive CLIPTAC partner to be used in control experiments. JQ1-TCO tert-butyl 6-hydroxyhexanoate, PPh 3 , DIAD, THF, r.t., 18 h; (c) 1. NaOH, THF, MeOH, r.t., 2 h. 2. 3-amino piperidine-2,6-dione HCl, pyridine, 110 °C, 17 h. 3. TFA, r.t., 3 h, 10% over 4 steps; (d) Tzamine, DIPEA, HATU, DMF, r.t., 2 h, 57%; (e) NaH, MeI, THF, r.t., 18 h, 69%; (f) DCM, TFA, r.t., 3 h, quant.; (g) DIPEA, HATU, TCO-amine, DMF, r.t., 16 h, 70% (JQ1-TCO) and 48% ((-)JQ1-TCO).
General Notes for Syntheses
Anhydrous solvents were purchased either from VWR or SeccoSolv and were stored under nitrogen. Other solvents were purchased from Fisher Chemicals. Commercially available reagents were used as received. TCO-Amine and TCO-NHS ester were purchased from Jena Bioscience. Petrol refers to the fraction with a boiling range between 40 and 60 ºC. All reactions were followed by TLC analysis (pre-coated TLC sheets ALUGRAM ® SIL G/UV 254 , Macherey-Nagel) or LC-MS (liquid chromatography mass spectrometry) on Agilent 1200 HPLC and 6140 MS using a YMC-Triart C18 column (50 x 2.0 mm, 1.9 µm). 1 H NMR spectra were recorded on a Bruker 400 UltraShield TM spectrometer. Chemical shifts are reported in parts per million (δ) referenced to the appropriate deuterated solvent employed and relative to TMS. Multiplicities are indicated by s (singlet), br s (broad singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet). 'Flash' column chromatography was performed on pre-packed silica cartridges (Biotage SNAP cartridges, KP-Sil) on Biotage Isolera Four. All reactions were carried out under nitrogen.
The purity of the final probes was determined by LC-MS and 1 H NMR and was always >95%. 
LC-MS methodology
12
A mixture of 3-hydroxyphtalic anhydride 11 (1.6 g, 9.8 mmol) in MeOH (25 mL) was refluxed for 3 hours. The mixture was cooled to room temperature and concentrated. The residue and NaHCO 3 (2.3 g, 27.3 mmol) were stirred in DMF (20 mL). Methyl iodide (1.46 mL, 23.4 mmol) was added and the reaction mixture was heated at 55 ºC for 3 hours. The reaction was cooled to room temperature and diluted with EtOAc (80 mL) and water (40 mL). The mixture was acidified with an aqueous solution of HCl (4N) and the aqueous layer was extracted with EtOAc (2 x 40 mL). The combined organic layers were washed with water (2 x 100), brine (2 x 100) and dried over MgSO 4 . The solvent was removed in vacuo and the crude product was purified by flash column chromatography with 3:7 EtOAc: Petrol to give 1,2-dimethyl 3-hydroxybenzene-1,2-dicarboxylate 12 (1.9 g, 9.1 mmol, 94%) as a pale pink oil. To a 0 °C mixture of tert-butyl 6-hydroxyhexanoate 12 (0.90 g, 4.76 mmol), triphenylphosphine (0.75 g, 2.86 mmol) and 1,2-dimethyl 3-hydroxybenzene-1,2-dicarboxylate (0.5 g, 2.38 mmol) in THF (4 mL), was added DIAD (0.56 mL, 2.86 mmol) dropwise. The mixture was stirred at room temperature for 18 hours. The solvent was removed in vacuo and the crude product was partitioned between EtOAc (20 mL) and water (20 mL). The organic phase was washed with brine (2 x 20 mL), dried over MgSO 4 and the solvent was removed in vacuo. The crude material and 3-aminopiperidine-2,6-dione hydrochloride (0.12 g, 0.75 mmol, 1.1 eq) were dissolved in pyridine (2.7 mL) and heated to 110 ºC for 17 hours. The mixture was cooled to room temperature. DCM (20 mL) and a 0.5 M HCl aqueous solution (10 mL) were added. The organic phase was extracted with DCM (3 x 20 mL). The organic phases were combined, dried over MgSO 4 and the solvent was removed in vacuo. The crude product was dissolved in TFA (4 mL) and the mixture was stirred at room temperature for 3 hours. The solvent was removed in vacuo and the crude material was dissolved in DCM (10 mL). The organic phase was extracted with a saturated solution of NaHCO 3 (4 x 20 mL). The aqueous phases were combined and acidified to pH 3 with a 1M HCl aqueous solution. The aqueous phase was then extracted with DCM (4 x 50 mL). The organic phases were combined, dried over MgSO 4 and the solvent was removed in vacuo to give 6-{[2-(2,6-dioxopiperidin-3-yl)- 2-(2,6-Dioxopiperidin-3-yl)-1,3-dioxo-2,3- 2-(1-methyl-2,6-dioxo piperidin-3-yl)-1,3-dioxo-2,3-dihydro-1H ] trideca-2(6),4,7,10,12-pentaen-9-yl]acetic acid. TFA salt (40 mg, 0.08 mmol), N,Ndiisopropylethylamine (41 µL, 0.23 mmol), HATU (30 mg, 0.08 mmol) and TCO-amine (18 mg, 0.08 mmol) were mixed in DMF (1 mL) and the reaction was stirred at room temperature for 16 hours. The solvent was removed in vacuo and the crude product was solubilised in diethyl ether (10 mL) and washed with a cold saturated solution of NaHCO 3 (3 x 10 mL). The organic phase was dried over MgSO 4 and the solvent was removed in vacuo. The crude product was purified by flash column chromatography with 1: 9 MeOH: DCM to give (4E)- (-)JQ1-TCO, (-)2: (4E)-Cyclooct-4-en-1-yl N-(3-{2-[(9R)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-tetraazatricyclo[8.3 ] tri deca-2(6),4,7,10,12-pentaen-9-yl]acetic acid. TFA salt (40 mg, 0.08 mmol), N,Ndiisopropylethylamine (41 µL, 0.23 mmol), HATU (30 mg, 0.08 mmol) and TCO-amine (18 mg, 0.08 mmol) were mixed in DMF (1 mL) and the reaction was stirred at room temperature for 16 hours. The solvent was removed in vacuo and the crude product was solubilised in diethyl ether (10 mL) and washed with a cold saturated solution of NaHCO 3 (3 x 10 mL). The organic phase was dried over MgSO 4 and the solvent was removed in vacuo. The crude product was purified by flash column chromatography with 1: 9 MeOH: DCM to give (4E)-cyclooct-4-en-1-yl N-(3-{2-[(9R)-7-(4-chlorophenyl)-4,5,13-trimethyl-3-thia-1,8,11,12-
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cyclooct-4-en-1-yl N-(3-{2-[(9S)-7-(4-chlorophenyl)-4,
